TOKYO, Mar 25 (Pulse News Wire) – SanBio Company Limited (4592.T) reported a lower net profit of ¥960 million for the fiscal year ending January 2026, compared to a loss of ¥896 million in the previous year. Research and development expenses surged to ¥321 million due to activities related to the approval process for its product Akougo®.
The company also highlighted significant progress in its regenerative medicine initiatives, particularly in the United States. It reached agreement with the FDA on the design of Phase 3 trials for traumatic brain injury (TBI).
Additionally, discussions are underway with PMDA regarding clinical trial designs for stroke and intracerebral hemorrhage. SanBio secured approximately ¥12.154 billion in growth capital through share issuance and expects ongoing costs associated with manufacturing, distribution, and sales infrastructure for Akougo®.
The firm anticipates further regulatory approvals and expansion of its therapeutic offerings across various neurological conditions.
🟡 Confidence: Standard AI-translated content.